Savara reports fourth quarter/year-end 2023 financial results and provides business update

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending december 31, 2023 and provided a business update. “we look forward to reporting impala-2 top line results at the end of the second quarter and, assuming positive data, anticipate filing the bla in the first half of 2025,” said matt pauls, chair and ceo, savara. “2023 was.
SVRA Ratings Summary
SVRA Quant Ranking